257 related articles for article (PubMed ID: 19459990)
21. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
[TBL] [Abstract][Full Text] [Related]
22. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
[TBL] [Abstract][Full Text] [Related]
23. Effect of GB virus C on response to antiretroviral therapy in HIV-infected Brazilians.
Souza IE; Zhang W; Diaz RS; Chaloner K; Klinzman D; Stapleton JT
HIV Med; 2006 Jan; 7(1):25-31. PubMed ID: 16313289
[TBL] [Abstract][Full Text] [Related]
24. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
Paton NI; Aboulhab J
HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
[TBL] [Abstract][Full Text] [Related]
25. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
Seyler C; Adjé-Touré C; Messou E; Dakoury-Dogbo N; Rouet F; Gabillard D; Nolan M; Toure S; Anglaret X
AIDS; 2007 May; 21(9):1157-64. PubMed ID: 17502726
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
[TBL] [Abstract][Full Text] [Related]
28. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
[TBL] [Abstract][Full Text] [Related]
29. Comparative potency of three antiretroviral therapy regimes in primary HIV infection.
Fidler S; Fraser C; Fox J; Tamm N; Griffin JT; Weber J
AIDS; 2006 Jan; 20(2):247-52. PubMed ID: 16511418
[TBL] [Abstract][Full Text] [Related]
30. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
[TBL] [Abstract][Full Text] [Related]
32. Viraemia and HIV-1 drug resistance mutations among patients receiving antiretroviral treatment in Mozambique.
Maldonado F; Biot M; Roman F; Masquelier C; Anapenge M; Bastos R; Chuquela HC; Arendt V; Schmit JC; Zachariah R
Trans R Soc Trop Med Hyg; 2009 Jun; 103(6):607-12. PubMed ID: 18804251
[TBL] [Abstract][Full Text] [Related]
33. A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.
Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B;
Arch Intern Med; 2003 May; 163(10):1220-6. PubMed ID: 12767960
[TBL] [Abstract][Full Text] [Related]
34. Impact of human immunodeficiency virus type 1 subtype on first-line antiretroviral therapy effectiveness.
Bocket L; Cheret A; Deuffic-Burban S; Choisy P; Gerard Y; de la Tribonnière X; Viget N; Ajana F; Goffard A; Barin F; Mouton Y; Yazdanpanah Y
Antivir Ther; 2005; 10(2):247-54. PubMed ID: 15865219
[TBL] [Abstract][Full Text] [Related]
35. Discordant response to HAART: reduction of viremia and replicative capacity of HIV strains in patients after genotype guided change of therapy.
Sarmati L; Montano M; Dori L; Buonomini AR; D'Ettorre G; Vullo V; Andreoni M
New Microbiol; 2004 Apr; 27(2 Suppl 1):95-8. PubMed ID: 15646070
[TBL] [Abstract][Full Text] [Related]
36. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.
Pujades-Rodríguez M; Schramm B; Som L; Nerrienet E; Narom P; Chanchhaya N; Ferradini L; Balkan S
Trop Med Int Health; 2011 Feb; 16(2):205-13. PubMed ID: 21087376
[TBL] [Abstract][Full Text] [Related]
37. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.
Bannister WP; Cozzi-Lepri A; Kjær J; Clotet B; Lazzarin A; Viard JP; Kronborg G; Duiculescu D; Beniowski M; Machala L; Phillips A;
J Antimicrob Chemother; 2011 Apr; 66(4):901-11. PubMed ID: 21393179
[TBL] [Abstract][Full Text] [Related]
38. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy.
Sheth PM; Kovacs C; Kemal KS; Jones RB; Raboud JM; Pilon R; la Porte C; Ostrowski M; Loutfy M; Burger H; Weiser B; Kaul R;
AIDS; 2009 Sep; 23(15):2050-4. PubMed ID: 19710596
[TBL] [Abstract][Full Text] [Related]
39. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study.
Boillat-Blanco N; Darling KE; Schoni-Affolter F; Vuichard D; Rougemont M; Fulchini R; Bernasconi E; Aouri M; Clerc O; Furrer H; Günthard HF; Cavassini M;
Antivir Ther; 2015; 20(2):165-75. PubMed ID: 24964403
[TBL] [Abstract][Full Text] [Related]
40. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml.
Easterbrook PJ; Ives N; Waters A; Mullen J; O'Shea S; Peters B; Gazzard BG
AIDS; 2002 Jul; 16(11):1521-7. PubMed ID: 12131190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
